Belgian biopharma sector flags decline amid budget cuts and falling exports

Belgium's biopharmaceutical sector is warning of a structural decline: drug reimbursement has fallen from 1.7% to 1.1% of GDP over two decades, medicine exports dropped 6.8% in 2025, investments fell 12% in 2024 and 4% in 2025, and over 400 jobs were lost between 2023 and 2025. Federal budget negotiations, including potential healthcare cuts, are compounding sector anxiety. The trend signals eroding competitiveness for a key Belgian export industry, though the direct policy impact remains uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works